Given our in vitro results concerning the increased cell’s invasive capabilities upon S100P inhibition in the context of wild-type E-cadherin, we evaluated the effect of S100P+ (graded as 3+, 2+, 1+) versus S100P− (graded as 0) in relapse-free survival among the better prognostic group of patients with E-cad+ tumours. The gene discussed is S100P; the disease is neoplasm.